Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of Dupilumab Coformulated With Berahyaluronidase Alfa in Healthy Participants
NCT07646548Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dupilumab (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Serum Concentration and Area Under the Curve from Time Zero to Last Quantifiable Concentration. Started Jun 2026; status: completed.
02
Drugs
Beyond the preview
Go deeper on NCT07646548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646548.